Clinica Universidad de Navarra   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Pamplona Spain (1962)

Organization Overview

First Clinical Trial
2002
NCT00844623
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Clinica Universidad de Navarra | Clínica Universidad de Navarra | Clinica Universidad de Navarra and Barcelona Institute of Global Health | Clínica Universidad de Navarra (Pamplona) | Clinica Universidad de Navarra, Universidad de Navarra | Clinica Universitaria de Navarra | Clinica Universitaria, Universidad de Navarra | Complejo Hospitalario de Navarra | Complejo Hospitalario de Navarra (Pamplona, Spain) | Hospital de Navarra | Hospital De Navarra Irunlarrea, Spain | Hospital of Navarra | Liver Unit, Clínica Universidad de Navarra | Navarra Clinic | Oncology Department. Clinica Universitaria de Navarra | Unidad de Investigacion Clinica. Clinica Universidad Navarra (CUN) | University of Navarra, Pamplona, Spain | University of Navarrra Hospital (Clinica Universitaria)

Active Ingredients

Drugs in Phase 4 Trials (25)

acetylcysteine (mucomyst) (1 trial)

amiodarone (cordarone) (1 trial)

bevacizumab (avastin) (3 trials)

capecitabine (xeloda) (2 trials)

cetuximab (erbitux) (2 trials)

daptomycin (cubicin) (1 trial)

dexmedetomidine (precedex) (2 trials)

digoxin (lanoxin) (1 trial)

fluorouracil (efudex) (4 trials)

fluticasone (cutivate) (1 trial)

formoterol (foradil) (1 trial)

irinotecan (Camptosar) (1 trial)

leucovorin (3 trials)

linezolid (zyvox) (1 trial)

magnesium citrate (1 trial)

oxaliplatin (eloxatin) (4 trials)

panitumumab (vectibix) (4 trials)

polyethylene glycol (1 trial)

propofol (diprivan) (1 trial)

sodium chloride (1 trial)

sodium picosulfate (1 trial)

teicoplanin (1 trial)

tigecycline (tygacil) (1 trial)

vancomycin (Vancocin) (1 trial)

vitamin c (1 trial)

Drugs in Phase 3 Trials (23)

alk alutard 5-grasses (1 trial)

anakinra (kineret) (1 trial)

atezolizumab (tecentriq) (1 trial)

bemiparin (Ivor) (1 trial)

bortezomib (velcade) (2 trials)

carboplatin (paraplatin) (1 trial)

carfilzomib (kyprolis) (2 trials)

cisplatin (platinol) (1 trial)

daratumumab (darzalex) (1 trial)

dexamethasone (3 trials)

doxorubicin (Doxil) (2 trials)

durvalumab (imfinzi) (1 trial)

enoxaparin (lovenox) (2 trials)

erlotinib (tarceva) (2 trials)

gemcitabine (gemzar) (2 trials)

house dust mite allergen (1 trial)

lenalidomide (revlimid) (2 trials)

melphalan (alkeran) (1 trial)

methylphenidate (ritalin) (1 trial)

methylprednisolone (medrol) (1 trial)

niraparib (zejula) (1 trial)

paclitaxel (taxol) (5 trials)

prednisone (meticorten) (2 trials)

Drugs in Phase 2 Trials (34)

aflibercept (zaltrap) (1 trial)

allogeneic adipose derived mesenchymal stem cell (4 trials)

allogeneic hematopoietic stem cells (Hemacord) (2 trials)

autologous dendritic cells (2 trials)

autologous dendritic cells transduced with ad encoding ns3 (1 trial)

autologous effector lymphocytes expanded ex-vivo (1 trial)

belantamab mafodotin (2 trials)

bo-112 (1 trial)

cyclophosphamide (cytoxan) (3 trials)

danegaptide (1 trial)

dasatinib (sprycel) (1 trial)

dendritic cells (1 trial)

epirubicin (ellence) (1 trial)

flidvax2006 (1 trial)

granisetron (kytril) (1 trial)

inp20 (1 trial)

ivermectin (stromectol) (1 trial)

memantine (namenda) (1 trial)

mitomycin (mutamycin) (1 trial)

nivolumab (opdivo) (3 trials)

omalizumab (xolair) (2 trials)

orteronel (1 trial)

palonosetron (aloxi) (1 trial)

platelet rich plasma (1 trial)

poly-iclc (1 trial)

rituximab (rituxan) (1 trial)

sarilumab (kevzara) (1 trial)

sirolimus (rapamune) (1 trial)

syl040012 (1 trial)

tremelimumab (2 trials)

tumor-pulsed dendritic cells (2 trials)

urelumab (1 trial)

vincristine (oncovin) (1 trial)

vismodegib (erivedge) (1 trial)

Drugs in Phase 1 Trials (15)

aldesleukin (proleukin) (1 trial)

autologous mesenchymal cells (1 trial)

autologous mesenchymal stem cells (1 trial)

autologous natural killer cells (1 trial)

autologous vitd3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (1 trial)

bilastine (1 trial)

dnx-2401 (1 trial)

dnx-2440 (1 trial)

pbf-1650 (1 trial)

peginterferon beta-1a (Plegridy) (1 trial)

pertuzumab (perjeta) (1 trial)

raav2/5-pbgd (1 trial)

syl-1001 (1 trial)

tk99un (1 trial)

trastuzumab (herceptin) (1 trial)

Drugs in Other Trials (19)

alpha-lipoic acid (1 trial)

boceprevir (victrelis) (1 trial)

cocoa bean (1 trial)

daclatasvir (daklinza) (1 trial)

dasabuvir (Exviera) (1 trial)

elbasvir (1 trial)

grazoprevir (zepatier) (1 trial)

icosapent ethyl (vascepa) (2 trials)

ledipasvir (Harvoni) (1 trial)

multivitamins (1 trial)

olive oil (1 trial)

ombitasvir (Viekira Pak) (1 trial)

omega-3 fatty acids (omacor) (1 trial)

paritaprevir (viekira pak) (1 trial)

ritonavir (Norvir) (1 trial)

simeprevir (olysio) (1 trial)

sofosbuvir (sovaldi) (1 trial)

telaprevir (incivek) (1 trial)

velpatasvir (Epclusa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute-On-Chronic Liver Failure (Phase 1)

Anemia (Phase 2)

Anus Neoplasms (Phase 2)

Asthenia (Phase 3)

Asthma (Phase 4)

Atrial Fibrillation (Phase 4)

Bacteremia (Phase 4)

Brain Stem Infarctions (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 3)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Small Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 3)

Cardiomyopathies (Phase 4)

Cardiomyopathy, Dilated (Phase 4)

Catheter-Related Infections (Phase 4)

Colonic Diseases (Phase 4)

Colonic Neoplasms (Phase 4)

Colorectal Neoplasms (Phase 2)

Communicable Diseases (Phase 2)

Coronavirus Infections (Phase 2)

End Stage Liver Disease (Phase 1)

Eye Pain (Phase 1)

Fibrosis (Phase 1)

Glaucoma (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 1)

Graft vs Host Disease (Phase 2)

Head and Neck Neoplasms (Phase 2)

Heart Failure (Phase 4)

Hepatic Insufficiency (Phase 1)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 1)

Infections (Phase 2)

Ischemia (Phase 4)

Klippel-Trenaunay-Weber Syndrome (Phase 2)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukopenia (Phase 2)

Liver Failure (Phase 1)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Multiple Myeloma (Phase 3)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Chronic Progressive (Phase 1)

Multiple Sclerosis, Relapsing-Remitting (Phase 1)

Neoplasm Metastasis (Phase 4)

Neoplasms, Plasma Cell (Phase 3)

Neoplasms, Second Primary (Phase 4)

Ocular Hypertension (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Ovarian Neoplasms (Phase 3)

Pancreatic Neoplasms (Phase 2)

Parkinson Disease (Phase 4)

Peanut Hypersensitivity (Phase 2)

Pneumonia (Phase 3)

Porphyria, Acute Intermittent (Phase 1)

Porphyria, Erythropoietic (Phase 1)

Porphyrias (Phase 1)

Psoriasis (Phase 1)

Pulmonary Fibrosis (Phase 1)

Rectal Neoplasms (Phase 2)

Recurrence (Phase 2)

Reperfusion Injury (Phase 4)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Sclerosis (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 3)

Sturge-Weber Syndrome (Phase 2)

Syndrome (Phase 2)

Thrombocytopenia (Phase 2)

Thrombosis (Phase 3)

Triple Negative Breast Neoplasms (Phase 2)

Urticaria (Phase 2)

Vomiting (Phase 2)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 79
  • # of Trial APIs: 116